PepGen Inc. (PEPG) Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT Data March 30, 2026 4:30 PM EDT
Company Participants
James McArthur – President, CEO, Treasurer, Secretary & Director
Paul Streck – Executive VP and Head of Research & Development
Conference Call Participants
Laurence Watts
Konstantinos Biliouris – Oppenheimer & Co. Inc., Research Division
Joseph Schwartz – Leerink Partners LLC, Research Division
Paul Matteis – Stifel, Nicolaus & Company, Incorporated, Research Division
Laura Chico – Wedbush Securities Inc., Research Division
Debjit Chattopadhyay – Guggenheim Securities, LLC, Research Division
Ananda Ghosh – H.C. Wainwright & Co, LLC, Research Division
Presentation
Operator
Welcome to the PepGen conference call to discuss top line results from lowest dose MAD cohort in the Phase II FREEDOM2 study, demonstrating promising safety, splicing and vHOT data. [Operator Instructions] As a reminder, this call is being recorded today, Monday, March 30, 2026.
I would now like to hand the conference call over to Laurence Watts of New Street Investor Relations. Please go ahead.
Laurence Watts
Thank you, operator. Joining us on the call today from PepGen are President and Chief Executive Officer, James McArthur; Executive Vice President, Head of Research and Development, Paul Streck; and Chief Financial Officer, Noel Donnelly.
During this call, management will make forward-looking statements, including statements related to its Phase II trial of PGN-EDODM1 as well as the timing of additional or future data from the studies and the company’s development plans. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties. Factors that could cause these results to be different from these statements include factors the company describes in its securities filings, including its annual report on Form 10-K and our quarterly reports on Form 10-Q. PepGen
Read the full article here